Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05912400 · ClinicalTrials.gov registry record
Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1
A clinical trial of Neurofibromatosis 1, sponsored by University of Arkansas.
- Completed
- Registry status
- 55
- Enrollment target
- 1
- Study location
NCT05912400: Completed study of Neurofibromatosis 1, sponsored by University of Arkansas.
NCT05912400 is a study of Neurofibromatosis 1 that has completed, run by University of Arkansas. The registered enrollment target is 55 participants, below the 1,033-participant average among 24 other Neurofibromatosis 1 trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05912400, a study of Neurofibromatosis 1, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
Neurofibromatosis type 1 is a common genetic disease with a broad spectrum of clinical manifestations in multiple organs of the body. This project will study the (dys)function of mitochondria in patients with neurofibromatosis through multiple collections of blood samples from patients and people not afflicted by neurofibromatosis (control group). This study will evaluate how the function of mitochondria changes with time and if medications and supplements can influence the function of the mitochondria. Patients will also answer questions regarding symptoms like fatigue and pain.
Primary Outcome
Mitochondrial respiration efficiency is measured here by the oxygen consumption rate (OCR) which is measured in units of picomoles per minute.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Blood draw
- OTHER FACIT-F and Pain Scales
Study Locations (1)
Arkansas
- University of Arkansas For Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2023-07-26 |
| Est. Completion | 2024-08-23 |
What the finished NCT05912400 record still lists
NCT05912400 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 1,033-participant average among 24 other Neurofibromatosis 1 trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Neurofibromatosis 1 appearing as the primary indexed condition, and to 2 interventions - of which Blood draw is the first listed.
NCT05912400 reports a single indexed study location in Arkansas.
Frequently Asked Questions
What is clinical trial NCT05912400 about?
NCT05912400 is a clinical study titled "Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1". Neurofibromatosis type 1 is a common genetic disease with a broad spectrum of clinical manifestations in multiple organs of the body. This project will study the (dys)function of mitochondria in patients with neurofibromatosis through multiple collections of blood samples from patients and people no...
What is the current status of trial NCT05912400?
This trial is currently completed. The enrollment target is 55 participants. The study started on 2023-07-26. Estimated completion is 2024-08-23.
What conditions does trial NCT05912400 study?
This clinical trial studies the following conditions: Neurofibromatosis 1.
What interventions are being tested in trial NCT05912400?
The interventions under investigation include: Blood draw (DIAGNOSTIC_TEST), FACIT-F and Pain Scales (OTHER).
Who is sponsoring clinical trial NCT05912400?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05912400 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurofibromatosis 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05912400's enrollment target sits among peer trials
55 17th of 24 higher than 7 of 24 other Neurofibromatosis 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neurofibromatosis 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1
RECRUITING · NA
-
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial
RECRUITING · NA
-
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
RECRUITING
-
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
RECRUITING · Phase 1
-
Tailoring an Online Platform to Promote Evidence-Based Care for Adults With Neurofibromatosis 1 and Low Health Literacy
RECRUITING · NA
-
Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI